Theratechnologies Inc. (THTX)
USD 2.57
(32.47%)
USD 2.57
(32.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 77.76 Million USD | -16.61% |
| 2022 | 93.26 Million USD | -21.77% |
| 2021 | 119.21 Million USD | 19.04% |
| 2020 | 100.14 Million USD | -14.81% |
| 2019 | 117.55 Million USD | 5.77% |
| 2018 | 111.14 Million USD | 87.93% |
| 2017 | 59.13 Million USD | 49.93% |
| 2016 | 39.44 Million USD | 4.97% |
| 2015 | 37.57 Million USD | 31.31% |
| 2014 | 28.61 Million USD | 22.0% |
| 2013 | 23.45 Million USD | -35.86% |
| 2012 | 36.57 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 71.99 Million USD | -7.43% |
| 2024 Q3 | 69.71 Million USD | -0.7% |
| 2024 Q2 | 70.2 Million USD | -2.48% |
| 2023 Q3 | 56.68 Million USD | -17.53% |
| 2023 Q1 | 79.24 Million USD | -15.03% |
| 2023 Q4 | 77.76 Million USD | 37.19% |
| 2023 FY | 77.76 Million USD | -16.61% |
| 2023 Q2 | 68.73 Million USD | -13.26% |
| 2022 Q2 | 95.35 Million USD | -12.25% |
| 2022 Q4 | 93.26 Million USD | -2.71% |
| 2022 Q3 | 95.85 Million USD | 0.52% |
| 2022 FY | 93.26 Million USD | -21.77% |
| 2022 Q1 | 108.67 Million USD | -8.84% |
| 2021 FY | 119.21 Million USD | 19.04% |
| 2021 Q3 | 127 Million USD | -4.88% |
| 2021 Q1 | 135.08 Million USD | 34.89% |
| 2021 Q4 | 119.21 Million USD | -6.13% |
| 2021 Q2 | 133.52 Million USD | -1.15% |
| 2020 Q1 | 110.66 Million USD | -5.86% |
| 2020 FY | 100.14 Million USD | -14.81% |
| 2020 Q2 | 111.75 Million USD | 0.98% |
| 2020 Q3 | 101.5 Million USD | -9.17% |
| 2020 Q4 | 100.14 Million USD | -1.34% |
| 2019 Q3 | 108.07 Million USD | -2.32% |
| 2019 Q1 | 116.49 Million USD | 4.84% |
| 2019 Q2 | 110.63 Million USD | -5.03% |
| 2019 FY | 117.55 Million USD | 5.77% |
| 2019 Q4 | 117.55 Million USD | 8.78% |
| 2018 Q2 | 54.08 Million USD | -4.11% |
| 2018 FY | 111.14 Million USD | 87.93% |
| 2018 Q1 | 56.39 Million USD | -4.64% |
| 2018 Q4 | 111.11 Million USD | 3.11% |
| 2018 Q3 | 107.75 Million USD | 99.26% |
| 2017 Q4 | 59.13 Million USD | 1.59% |
| 2017 FY | 59.13 Million USD | 49.93% |
| 2017 Q3 | 58.21 Million USD | 3.68% |
| 2017 Q2 | 56.14 Million USD | 7.8% |
| 2017 Q1 | 52.08 Million USD | 32.04% |
| 2016 Q2 | 39.77 Million USD | 5.69% |
| 2016 FY | 39.44 Million USD | 4.97% |
| 2016 Q4 | 39.44 Million USD | 2.13% |
| 2016 Q3 | 38.62 Million USD | -2.89% |
| 2016 Q1 | 37.63 Million USD | 0.14% |
| 2015 Q3 | 39.12 Million USD | 28.21% |
| 2015 FY | 37.57 Million USD | 31.31% |
| 2015 Q2 | 30.51 Million USD | 5.0% |
| 2015 Q4 | 37.57 Million USD | -3.96% |
| 2015 Q1 | 29.06 Million USD | 1.56% |
| 2014 Q3 | 30.24 Million USD | -11.78% |
| 2014 Q2 | 34.28 Million USD | 79.28% |
| 2014 Q1 | 19.12 Million USD | -18.48% |
| 2014 FY | 28.61 Million USD | 22.0% |
| 2014 Q4 | 28.61 Million USD | -5.37% |
| 2013 Q2 | 28.7 Million USD | -11.57% |
| 2013 FY | 23.45 Million USD | -35.86% |
| 2013 Q4 | 23.45 Million USD | -8.76% |
| 2013 Q3 | 25.71 Million USD | -10.42% |
| 2013 Q1 | 32.45 Million USD | -11.26% |
| 2012 FY | 36.57 Million USD | 0.0% |
| 2012 Q4 | 36.57 Million USD | -11.67% |
| 2012 Q2 | 41.6 Million USD | -9.58% |
| 2012 Q1 | 46 Million USD | -10.15% |
| 2012 Q3 | 41.4 Million USD | -0.47% |
| 2011 Q1 | 66.43 Million USD | -5.47% |
| 2011 Q4 | 51.2 Million USD | -11.41% |
| 2011 Q3 | 57.8 Million USD | -8.2% |
| 2011 Q2 | 62.96 Million USD | -5.23% |
| 2010 Q4 | 70.27 Million USD | 46.82% |
| 2010 Q1 | 58.88 Million USD | -9.94% |
| 2010 Q2 | 54.83 Million USD | -6.87% |
| 2010 Q3 | 47.86 Million USD | -12.71% |
| 2009 Q4 | 65.38 Million USD | -4.0% |
| 2009 Q1 | 61.96 Million USD | 43.73% |
| 2009 Q2 | 65.03 Million USD | 4.95% |
| 2009 Q3 | 68.1 Million USD | 4.72% |
| 2008 Q3 | 68.15 Million USD | -19.13% |
| 2008 Q1 | 94.42 Million USD | 26.66% |
| 2008 Q2 | 84.27 Million USD | -10.75% |
| 2008 Q4 | 43.11 Million USD | -36.74% |
| 2007 Q2 | 85.36 Million USD | 0.95% |
| 2007 Q3 | 80.14 Million USD | -6.12% |
| 2007 Q1 | 84.56 Million USD | 89.39% |
| 2007 Q4 | 74.55 Million USD | -6.98% |
| 2006 Q2 | 57.12 Million USD | 32.23% |
| 2006 Q1 | 43.2 Million USD | -5.94% |
| 2006 Q3 | 51.39 Million USD | -10.03% |
| 2006 Q4 | 44.65 Million USD | -13.13% |
| 2005 Q3 | 49.03 Million USD | -3.58% |
| 2005 Q4 | 45.93 Million USD | -6.34% |
| 2005 Q2 | 50.86 Million USD | -19.41% |
| 2005 Q1 | 63.11 Million USD | 10.29% |
| 2004 Q1 | 77.59 Million USD | 6.47% |
| 2004 Q2 | 69.84 Million USD | -9.99% |
| 2004 Q3 | 58.53 Million USD | -16.19% |
| 2004 Q4 | 57.22 Million USD | -2.24% |
| 2003 Q2 | 89.05 Million USD | 0.16% |
| 2003 Q3 | 83.36 Million USD | -6.39% |
| 2003 Q1 | 88.91 Million USD | -0.96% |
| 2003 Q4 | 72.87 Million USD | -12.59% |
| 2002 Q4 | 89.78 Million USD | -5.51% |
| 2002 Q1 | 102.56 Million USD | 13.49% |
| 2002 Q2 | 99.19 Million USD | -3.29% |
| 2002 Q3 | 95.01 Million USD | -4.21% |
| 2001 Q1 | 52.97 Million USD | -3.66% |
| 2001 Q4 | 90.37 Million USD | -3.1% |
| 2001 Q3 | 93.27 Million USD | 75.1% |
| 2001 Q2 | 53.26 Million USD | 0.55% |
| 2000 Q1 | 20.19 Million USD | 10.12% |
| 2000 Q4 | 54.99 Million USD | 14.63% |
| 2000 Q3 | 47.97 Million USD | 16.88% |
| 2000 Q2 | 41.04 Million USD | 103.27% |
| 1999 Q4 | 18.33 Million USD | -2.82% |
| 1999 Q1 | 11.73 Million USD | -5.64% |
| 1999 Q3 | 18.86 Million USD | 24.76% |
| 1999 Q2 | 15.12 Million USD | 28.89% |
| 1998 Q2 | 13.86 Million USD | 84.46% |
| 1998 Q3 | 12.78 Million USD | -7.83% |
| 1998 Q4 | 12.43 Million USD | -2.71% |
| 1998 Q1 | 7.51 Million USD | -11.58% |
| 1997 Q4 | 8.5 Million USD | -12.51% |
| 1997 Q1 | 11.39 Million USD | 0.0% |
| 1997 Q3 | 9.71 Million USD | -3.63% |
| 1997 Q2 | 10.08 Million USD | -11.52% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 93.198% |
| Embecta Corp. | 1.21 Billion USD | 93.596% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 91.401% |
| Dynavax Technologies Corporation | 997.09 Million USD | 92.2% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 62.211% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 95.06% |
| PainReform Ltd. | 9.93 Million USD | -683.172% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -35.444% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -184.379% |
| SCYNEXIS, Inc. | 128.41 Million USD | 39.438% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -236.268% |
| Cosmos Health Inc. | 66.29 Million USD | -17.306% |
| Journey Medical Corporation | 76.84 Million USD | -1.197% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -184.379% |
| Safety Shot Inc | 12.7 Million USD | -511.912% |
| Alpha Teknova, Inc. | 128.58 Million USD | 39.52% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 89.322% |
| Bright Green Corporation | 17.4 Million USD | -346.87% |
| Procaps Group, S.A. | 460.18 Million USD | 83.101% |
| Harrow Health, Inc. | 311.75 Million USD | 75.054% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -422.185% |
| Biofrontera Inc. | 27.93 Million USD | -178.423% |
| DURECT Corporation | 45.18 Million USD | -72.097% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 94.48% |
| Cronos Group Inc. | 1.13 Billion USD | 93.144% |
| OptiNose, Inc. | 107.72 Million USD | 27.811% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 83.491% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -39.0% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -237.435% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 83.095% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -552.524% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 4.9% |
| Radius Health, Inc. | 1.71 Billion USD | 95.468% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -45.944% |
| ProPhase Labs, Inc. | 91.92 Million USD | 15.401% |
| Phibro Animal Health Corporation | 982.18 Million USD | 92.082% |
| Procaps Group S.A. | 460.18 Million USD | 83.101% |
| Alvotech | 950.09 Million USD | 91.815% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -79.568% |
| Viatris Inc. | 47.68 Billion USD | 99.837% |
| Rockwell Medical, Inc. | 52.17 Million USD | -49.06% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 34.147% |
| SIGA Technologies, Inc. | 254.83 Million USD | 69.483% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.206% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 71.586% |
| Shineco, Inc. | 84.17 Million USD | 7.615% |
| PetIQ, Inc. | 868.22 Million USD | 91.043% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -821.629% |
| Incannex Healthcare Limited | 17.04 Million USD | -356.203% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.608% |
| Alimera Sciences, Inc. | 153.52 Million USD | 49.344% |
| Silver Spike Investment Corp. | 88.57 Million USD | 12.201% |
| Assertio Holdings, Inc. | 286.41 Million USD | 72.848% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1206.661% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -130.114% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -148.917% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -487.045% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 70.218% |
| Hempacco Co., Inc. | 18.04 Million USD | -331.018% |
| Talphera, Inc. | 20.39 Million USD | -281.314% |
| Alvotech | 950.09 Million USD | 91.815% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 80.853% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 95.29% |
| Currenc Group, Inc. | 141.49 Million USD | 45.036% |
| Kamada Ltd. | 351.96 Million USD | 77.905% |
| Indivior PLC | 1.95 Billion USD | 96.014% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1000.212% |
| Flora Growth Corp. | 23.62 Million USD | -229.167% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -487.045% |
| Evolus, Inc. | 188.99 Million USD | 58.852% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 93.923% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 94.86% |
| Akanda Corp. | 8.83 Million USD | -779.741% |